Arbutus Biopharma
ABUS
ABUS
77 hedge funds and large institutions have $616M invested in Arbutus Biopharma in 2015 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
57% more funds holding
Funds holding: 49 → 77 (+28)
Holders
77
Holding in Top 10
2
Calls
$10.3M
Puts
$3.78M
Top Buyers
| 1 | +$280M | |
| 2 | +$47.4M | |
| 3 | +$38.8M | |
| 4 |
BRC
Blue Ridge Capital
New York
|
+$29.7M |
| 5 |
D.E. Shaw & Co
New York
|
+$28.4M |
Top Sellers
| 1 | -$5.3M | |
| 2 | -$1.89M | |
| 3 | -$1.44M | |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$1.11M |
| 5 |
IGIM
I.G. Investment Management
Winnipeg,
Manitoba, Canada
|
-$976K |